TerminatedPhase 1NCT03399448
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
Studying Myxoid/round cell liposarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Pennsylvania
- Principal Investigator
- Edward Stadtmauer, MDUniversity of Pennsylvania
- Intervention
- NY-ESO-1 redirected autologous T cells with CRISPR edited endogenous TCR and PD-1(biological)
- Enrollment
- 3 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2018 – 2020
Study locations (1)
- University of Pennsylvania, Philadelphia, Pennsylvania, United States
Collaborators
Parker Institute for Cancer Immunotherapy · Gilead Sciences
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03399448 on ClinicalTrials.govOther trials for Myxoid/round cell liposarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT06644755First-in-Human Trial of DS-2243a in Participants With Advanced Solid TumorsDaiichi Sankyo
- RECRUITINGPHASE1NCT06414434BTX-A51 in Patients With Liposarcoma or CIC-rearranged SarcomaMichael Wagner, MD
- RECRUITINGPHASE1NCT06083883Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1M.D. Anderson Cancer Center
- ACTIVE NOT RECRUITINGPHASE1NCT05492682START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of CancerValo Therapeutics Oy
- ACTIVE NOT RECRUITINGPHASE2NCT04044768Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell LiposarcomaUSWM CT, LLC